Net sales surged over 270% year-over-year, driven by neurosurgery growth, while losses narrowed and the company shifted focus exclusively to high-margin neurosurgery. Board changes and cost reductions position CLS for sustainable profitability.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.